MedTrace Logo

The Early Medication Change (EMC) Trial

NCT00974155 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 889

Last updated 2015-04-01

No results posted yet for this study

Summary

The EMC trial investigates for the first time prospectively whether Major Depression Disorder patients with non-improvement after 14 days of antidepressive treatment with EMC are more likely to become remitters compared to patients treated according to current guidelines, i.e., with a medication change after 28 days of treatment in case of non-response.

Conditions

Interventions

DRUG

Escitalopram, venlafaxine, lithium

oral application, highest tolerable dose, once daily

DRUG

Escitalopram, venlafaxine

oral application, highest tolerable dose, once daily

Sponsors & Collaborators

  • German Federal Ministry of Education and Research

    collaborator OTHER_GOV

  • K. Lieb

    lead OTHER

Principal Investigators

  • Klaus Lieb, Prof. · Clinic of Psychiatry and Psychotherapy Mainz

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00974155 on ClinicalTrials.gov